Docket No.: VTOB.138NP Customer No. 20,995

CONTINUATION OF INFORMATION DISCLOSURE STATEMENT

Applicant : Mark Conkling

App. No 10/559,113

Filed : April 21, 2006

For METHOD OF REDUCING THE

HARMFUL EFFECTS OF ORALLY OR TRANSDERMALLY DELIVERED

NICOTINE

Examiner Unassigned : 1731

Mail Stop Amendment

Art Unit

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir

Continuing the Information Disclosure Statement under EFS ID # 1524749 submitted herewith our additional references listed on said Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted.

(619) 235-8550

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:	Ву:	/Eric S. Furman/
	Eric S. Furman, Ph.D. Registration No. 45,664	
	Attorney of Record	